Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies
Executive Summary
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.
You may also be interested in...
Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Allergan’s Saunders Speaks Of Urgency, But Not Of Specifics
Days after surviving a shareholder vote to split up his roles, chairman/CEO Saunders says unhappy investors have been heard and change is coming. As for details, everything is on the table.
Aptinyx Sees Path Forward In DPN With Long-Term Patients
After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.
Need a specific report? 1000+ reports available
Buy Reports